Spero Therapeutics
NEWS
It was another busy week of clinical trial announcements. Here’s a look.
It was a busy week for clinical trial updates. Here’s a look.
It was a busy week for biopharma, biotech and medical device initial public offerings (IPOs). Here’s a look.
Presentations will highlight the potential for oral SPR994 to change the treatment landscape in cUTI and the opportunity for oral SPR720 in NTM
The Fund has now invested a total of USD 30 million in six companies
There is, thankfully, no age limit on innovation—you can do it at any age. But for many, “young,” counts as under 30, sometimes under 35, or even under 40, at least in terms of putting together lists of scientific innovators.
Spero Therapeutics, Inc. announced that it entered into a collaboration with the Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis, an indication that is designated as a critical concern by the World Health Organization.
There are currently no oral antibiotics specifically approved for use to treat pulmonary NTM infections. If successfully developed, SPR720 has the potential to address an important unmet need as the first oral antibiotic.
Shares of Cambridge, Mass.-based Spero Therapeutics are climbing this morning after the company announced it secured up to $54 million from the government to support its development of SPR944 as a potential treatment against drug-resistant infections.
JOBS
IN THE PRESS